Table 1. Patient demographics, reason for sending DOAC level, and results of DOAC testing.

Patient	Reason for testing	Age (years)	Gender M=male, F= female	BMI (kg/m2)	Weight (kg)	Dose (QD= daily, BID=twice daily)	DOAC level (ng/ml)*	Peak vs trough	Miscellaneous Notes	Outcome
Apixaban
1	obesity	64	F	50.7	139.8	5 mg BID	240.3	peak		no change
2	obesity	41	F	66.8	199.1	5 mg BID	110.6	peak		no change
3	low body weight	88	F	22.6	54.3	2.5 mg BID	102	trough		no change
							218.5	peak
4	recurrent TTP with stroke on apixaban	45	F	34.5	82.8	5 mg BID	229.5	peak	inpatient	stopped apixaban, resumed aspirin
5	Livedoid vasculopathy with persistent symptoms in spite of a/c	66	M	28.1	90.2	5 mg BID	93.3	random	8 hour post dose	no change
6	healing leg ulcer with palpable clotted veins around it	28	M	27.3	86.2	5 mg BID	159	peak	4 hours post dose	no acute thrombus, no change to dose
7	progressive superior mesenteric vein thrombosis in spite of apixaban	62	F	46.2	-	7.5 mg BID	274	peak	inpatient; 4 hour post dose	switched to LMWH in setting of malignancy
8	unclear	70	F	27.4	70.2	5 mg BID	269.2	trough		no change
Rivaroxaban
9	obesity	27	M	56.2	203.9	15 mg BID	0	trough	17 hours post-dose	no change
10	obesity	40	M	43.6	-	20 mg QD	222.3	peak	3 hours post-dose	no change
11	obesity	47	M	40.7	150	20 mg QD	15.5	trough		no change
							205.6	peak	2.5 hours post-dose
12	obesity	33	F	51.2	148.3	20 mg QD	96.5	random		no change
							37.8	trough
							459.8	peak
13	obesity	43	M	44.9	158.8	20 mg QD	142.4	peak		no change
							17	trough
							134	random		no change
14	obesity	47	F	59.3	161.6	20 mg QD	139.1	random	no documentation	no change
15	obesity	47	F	50.1	140.6	20 mg QD	0	trough	24 hours	no change
							123.7	peak	2.5 hours post-dose
16	low body weight	30	F	20	44.5	15 mg QD	155.5	peak		no change
							5.8	peak		no change
							116	peak		no change
17	concern for new thrombus, rule out anticoagulation failure	38	M	26.6	96.5	15 mg BID	161.6	peak		determined thrombus developed prior to rivaroxaban inittiation; thus no change
18	history of supratherapeutic INR on warfarin, concern for overdosing of rivaroxaban	29	F	22.8	60.1	20 mg QD	19.4	random		no change
19	history of bleeding at lower dose	54	F	NR	NR	20 mg QD	282.6	peak	3 hours post-dose	no change
20	starting terbinafine- concern for medication interaction	53	M	31.6	103.4	20 mg QD	250.3	peak		no change
	post-terbinafine dose						210.1	peak	level checked one week after starting terbinafine	no change
21	post gastric bypass	60	F	30.9	100.4	20 mg QD	125.8	peak	4 hours post-dose	no change
22	s/p bowel resection	21	M	30.9	106.2	20 mg QD	0	random		no change
23	unclear	70	M	27.6	87.3	20 mg QD	194	peak	4 hours after last dose	no change
Dabigatran
24	acute on chronic renal failure, need for line placement	59	M	37.6	NR	150 mg QD	194	random	7d after last dose	monitored level until renal biopsy performed without complication
							155	random	8d post-dose
							128	random	9d post-dose
							117	random	10d post-dose
							88	random	11d post-dose
							66	random	12d post-dose
							66	random	13d post-dose
							44	random	15d post-dose
							54	random	16.5d post-dose
25	need for urgent surgical intervention	75	M	25.2	NR	NR	91.72	random	24 hours post-dose	levels monitored in preparation for surgery; ultimately never underwent surgery
							65	random	48 hours post-dose
							46.1	random	7d post-dose
26	pre-op	65	F	14.9	81.6	150 mg BID	<30	random	24 hours post-dose	repair of wound dehiscience of deep brain stimulator
27	APLAS	21	F	21.9	NR	150 mg BID	85.11	peak	1 hour post-dose	no change
28	prolonged PT/PTT	59	F	NR	108	150 mg BID	92	random		dabigatran held in setting of prolonged PTT/PT due to liver synthetic dysfunction

^*Determined by liquid chromatography- mass spectrometry (LC-MS) and reported as anti-Xa drug level for apixaban and rivaroxaban and by chromogenic ecarin assay for dabigatran

Abbreviations: BMI= body mass index; INR= international normalized ratio; APLAS = anti-phospholipid antibody syndrome; PT= prothrombin time; PTT= partial thromboplastin time; d=days, hrs= hours